Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

2.1 Polatuzumab vedotin (Polivy, Roche) in combination with bendamustine and rituximab is indicated for 'the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The cost per item from the company's submission is £11,060 per 140‑mg vial (excluding VAT; British national formulary online accessed July 2020). The company estimates that the average cost of a course of treatment is £50,416.

2.4 The company has a commercial arrangement. This makes polatuzumab vedotin available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.